摘要
目的探讨弥漫大B细胞淋巴瘤(DLBCL)患者血清可溶性CD155(sCD155)、可溶性CD163(sCD163)与化疗疗效和预后的关系。方法前瞻性选取2018年5月至2020年5月邯郸市中心医院收治的126例DLBCL患者(DLBCL组)及126例健康体检者(对照组),比较两组血清sCD155、sCD163水平。根据DLBCL患者化疗效果分为有效组和无效组,比较治疗前后的血清sCD155、sCD163水平。比较不同血清sCD155、sCD163水平患者化疗的有效率。采用Kaplan-Meier法分析不同血清sCD155、sCD163水平与DLBCL患者3年总体生存期(OS)及无进展生存期(PFS)的关系。采用Cox比例风险回归模型分析影响DLBCL患者预后的因素。结果DLBCL组治疗前血清sCD155、sCD163水平均高于对照组(均P<0.05)。本组126例DLBCL患者化疗有效率为69.8%(88/126),与有效组相比,无效组治疗前、后的血清sCD155、sCD163水平均更高(均P<0.05);与治疗前比较,有效组治疗后血清sCD155、sCD163水平均降低(均P<0.05)。sCD155、sCD163高水平组DLBCL患者有效率分别低于sCD155、sCD163低水平组(均P<0.05)。Kaplan-Meier法分析显示,sCD155、sCD163低水平组DLBCL患者的3年OS、PFS高于高水平组(均P<0.05)。高水平sCD155、sCD163均是影响DLBCL患者3年PFS、OS的独立风险因素(均P<0.05)。结论DLBCL患者血清sCD155、sCD163水平异常升高,可降低化疗疗效并导致不良预后。
Objective To investigate the relationship between serum soluble CD155(sCD155),soluble CD163(sCD163)and chemotherapy efficacy and prognosis in patients with diffuse large B-cell lymphoma(DLBCL).Methods A total of 126 patients with DLBCL admitted to Handan Central Hospital from May 2018 to May 2020(DLBCL group)and 126 healthy subjects(control group)were prospectively selected to compare serum sCD155 and sCD163 levels.According to the chemotherapy effect of DLBCL patients,they were divided into effective group and ineffective group,and the serum sCD155 and sCD163 levels were compared before and after treatment.The effective rate of chemotherapy in patients with different serum sCD155 and sCD163 levels was compared.Kaplan-Meier method was used to analyze the relationship between serum sCD155 and sCD163 levels and 3-year overall survival(OS)and progression-free survival(PFS)of DLBCL patients.Cox proportional risk regression model was used to analyze the prognostic factors of DLBCL patients.Results The serum levels of sCD155 and sCD163 in DLBCL group were higher than those in control group before treatment(all P<0.05).The effective rate of chemotherapy in 126 DLBCL patients in this group was 69.8%(88/126).Compared with the effective group,the serum levels of sCD155 and sCD163 were higher in the ineffective group before and after treatment(all P<0.05).Compared with before treatment, serum sCD155 and sCD163 levels in the effective group were decreased aftertreatment (all P<0. 05). The effective rate of DLBCL patients in sCD155 and sCD163 high level groupswas lower than that in sCD155 and sCD163 low level groups ( all P<0. 05). Kaplan-Meier analysis showedthat the 3-year OS and PFS of DLBCL patients in the low level group of sCD155 and sCD163 were higherthan those in the high level group (all P<0. 05). The high level of sCD155 and sCD163 were independentrisk factors for 3-year PFS and OS in DLBCL patients (all P <0. 05). Conclusions Abnormal levels ofserum sCD155 and sCD163 in DLBCL patients may reduce the efficacy of che
作者
付进杰
马晓军
申克明
王晓阳
范高峰
董会会
李秀英
刘永芳
Fu Jinjie;Ma Xiaojun;Sheng Keming;Wang Xiaoyang;Fan Gaofeng;Dong Huihui;Li Xiuying;Liu Yongfang(Second Department of Hematology,Handan Central Hospital,Handan 056001,China)
出处
《中国医师杂志》
CAS
2024年第10期1519-1524,共6页
Journal of Chinese Physician
基金
河北省医学科学研究重点课题(20181676)。
